基于奥美沙坦酯治疗方案在高血压患者中的疗效
Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients.
作者信息
Oparil Suzanne, Chrysant Steven G, Kereiakes Dean, Xu Jianbo, Chavanu Kathleen J, Waverczak William, Dubiel Robert
机构信息
Division of Cardiovascular Diseases, University of Alabama at Birmingham School of Medicine, AL, USA.
出版信息
J Clin Hypertens (Greenwich). 2008 Dec;10(12):911-21. doi: 10.1111/j.1751-7176.2008.00045.x.
The efficacy and safety of an olmesartan medoxomil (OM)-based treatment algorithm was tested in a double-blind, randomized, placebo-controlled titration study in 276 patients with stage 1 or 2 hypertension. After placebo run-in, patients were randomized to placebo (12 weeks) or OM 20 mg/d (weeks 1-3). OM was up-titrated to 40 mg/d (weeks 4-6), then OM/hydrochlorothiazide (HCTZ) 40/12.5 mg/d (weeks 7-9) and OM/HCTZ 40/25 mg/d (weeks 10-12) were started if blood pressure (BP) remained > or =120/80 mm Hg at each time interval. End points were change from baseline in mean systolic BP (primary) and mean diastolic BP (secondary). OM-based treatment was well tolerated and changed BP by -22.3/-12.1 mm Hg from baseline vs -0.1/+0.8 mm Hg for placebo (P<.0001). Cumulative goal BP (<140/90 mm Hg) was achieved in 74.1% and 30.7% of OM- compared with placebo-treated patients, respectively (P<.0001). BP normalized (<120/80 mm Hg) in 44.8% of OM- vs 1.4% of placebo-treated patients with stage 1 hypertension (P<.0001).
在一项针对276例1或2期高血压患者的双盲、随机、安慰剂对照滴定研究中，测试了基于奥美沙坦酯（OM）的治疗方案的疗效和安全性。在安慰剂导入期后，患者被随机分为接受安慰剂治疗（12周）或OM 20 mg/d治疗（第1 - 3周）。若在每个时间间隔血压（BP）仍≥120/80 mmHg，则将OM剂量上调至40 mg/d（第4 - 6周），然后开始使用OM/氢氯噻嗪（HCTZ）40/12.5 mg/d（第7 - 9周）和OM/HCTZ 40/25 mg/d（第10 - 12周）。终点指标为平均收缩压相对于基线的变化（主要指标）和平均舒张压相对于基线的变化（次要指标）。基于OM的治疗耐受性良好，与安慰剂相比，血压从基线下降了-22.3/-12.1 mmHg，而安慰剂组为-0.1/+0.8 mmHg（P<0.0001）。与安慰剂治疗的患者相比，接受OM治疗的患者累积达到目标血压（<140/90 mmHg）的比例分别为74.1%和30.7%（P<0.0001）。在1期高血压患者中，接受OM治疗的患者血压正常化（<120/80 mmHg）的比例为44.8%，而接受安慰剂治疗的患者为1.4%（P<0.0001）。
Zotero 插件